Genus announces collaboration with Caribou Biosciences

Caribou’s CRISPR-Cas9 technology accurately targets and cuts DNA to produce precise and controllable changes to the genome.

Genus said the collaboration was a significant move for the company, making the largest technology-driven alliance it has made to date.

Genus did not disclose any financial details but said the agreement gives it exclusive access to Caribou's technology for the development of new traits in pigs, cattle and potentially other livestock species.

In addition to an upfront payment, Caribou is eligible to receive regulatory and commercial milestone payments and royalties on licensed product sales from Genus.

The companies will collaborate during a four-year research programme funded by Genus, which may be extended for an additional three years.

Dr. Jonathan Lightner, chief scientific officer and head of R&D of Genus, said: “This latest investment into genome editing ensures Genus will remain at the forefront of the development and application of technology to support the well-being of livestock.

“This relationship will enable new and exciting research opportunities that will strengthen and accelerate Genus' gene editing capabilities.”

At 0956 BST, Genus shares were down 4.7% to 1,497p.